Literature DB >> 26052448

Ebolavirus and Haemorrhagic Syndrome.

Gerald A Matua1, Dirk M Van der Wal2, Rozzano C Locsin3.   

Abstract

The Ebola virus is a highly virulent, single-stranded ribonucleic acid virus which affects both humans and apes and has fast become one of the world's most feared pathogens. The virus induces acute fever and death, with haemorrhagic syndrome occurring in up to 90% of patients. The known species within the genus Ebolavirus are Bundibugyo, Sudan, Zaïre, Reston and Taï Forest. Although endemic in Africa, Ebola has caused worldwide anxiety due to media hype and concerns about its international spread, including through bioterrorism. The high fatality rate is attributed to unavailability of a standard treatment regimen or vaccine. The disease is frightening since it is characterised by rapid immune suppression and systemic inflammatory response, causing multi-organ and system failure, shock and often death. Currently, disease management is largely supportive, with containment efforts geared towards mitigating the spread of the virus. This review describes the classification, morphology, infective process, natural ecology, transmission, epidemic patterns, diagnosis, clinical features and immunology of Ebola, including management and epidemic containment strategies.

Entities:  

Keywords:  Disease Management; Ebolavirus; Filoviridae; Hemorrhage; Hemorrhagic Fever, Ebola; Pathogenicity Factors; Virulence

Year:  2015        PMID: 26052448      PMCID: PMC4450778     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  26 in total

Review 1.  Recent advances in Ebolavirus vaccine development.

Authors:  Jason S Richardson; Joseph D Dekker; Maria A Croyle; Gary P Kobinger
Journal:  Hum Vaccin       Date:  2010-06-01

Review 2.  Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.

Authors:  E M Leroy; J-P Gonzalez; S Baize
Journal:  Clin Microbiol Infect       Date:  2011-07       Impact factor: 8.067

3.  WHO gives go ahead for experimental treatments to be used in Ebola outbreak.

Authors:  Anna Sayburn
Journal:  BMJ       Date:  2014-08-13

4.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

5.  Inflammatory responses in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; A J Georges; M-C Georges-Courbot; M Capron; I Bedjabaga; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 6.  Progress in filovirus vaccine development: evaluating the potential for clinical use.

Authors:  Darryl Falzarano; Thomas W Geisbert; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

Review 7.  Current ebola vaccines.

Authors:  Thomas Hoenen; Allison Groseth; Heinz Feldmann
Journal:  Expert Opin Biol Ther       Date:  2012-05-05       Impact factor: 4.388

Review 8.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

9.  Experimental inoculation of plants and animals with Ebola virus.

Authors:  R Swanepoel; P A Leman; F J Burt; N A Zachariades; L E Braack; T G Ksiazek; P E Rollin; S R Zaki; C J Peters
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

10.  Reemerging Sudan Ebola virus disease in Uganda, 2011.

Authors:  Trevor Shoemaker; Adam MacNeil; Stephen Balinandi; Shelley Campbell; Joseph Francis Wamala; Laura K McMullan; Robert Downing; Julius Lutwama; Edward Mbidde; Ute Ströher; Pierre E Rollin; Stuart T Nichol
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

View more
  5 in total

1.  Disaster Preparedness: Need for inclusion in undergraduate nursing education.

Authors:  Susan Achora; Joy K Kamanyire
Journal:  Sultan Qaboos Univ Med J       Date:  2016-02-02

Review 2.  The Development of mRNA Vaccines for Infectious Diseases: Recent Updates.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Infect Drug Resist       Date:  2021-12-09       Impact factor: 4.003

3.  Predicting and Evaluating the Epidemic Trend of Ebola Virus Disease in the 2014-2015 Outbreak and the Effects of Intervention Measures.

Authors:  Zuiyuan Guo; Dan Xiao; Dongli Li; Xiuhong Wang; Yayu Wang; Tiecheng Yan; Zhiqi Wang
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

4.  The Role of the Polio Program Infrastructure in Response to Ebola Virus Disease Outbreak in Nigeria 2014.

Authors:  Rui G Vaz; Pascal Mkanda; Richard Banda; William Komkech; Olubowale O Ekundare-Famiyesin; Rosemary Onyibe; Sunday Abidoye; Peter Nsubuga; Sylvester Maleghemi; Bolatito Hannah-Murele; Sisay G Tegegne
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

Review 5.  mRNA vaccines for COVID-19 and diverse diseases.

Authors:  Abid Hussain; Haiyin Yang; Mengjie Zhang; Qing Liu; Ghallab Alotaibi; Muhammad Irfan; Huining He; Jin Chang; Xing-Jie Liang; Yuhua Weng; Yuanyu Huang
Journal:  J Control Release       Date:  2022-03-21       Impact factor: 11.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.